Quantcast
Last updated on April 16, 2014 at 11:49 EDT

Latest Channelopathy Stories

2013-08-07 16:27:15

Technology Holds Promise for People Suffering From Macular Degeneration and Retinitis Pigmentosa IRVINE, Calif., Aug. 7, 2013 /PRNewswire/ -- EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented a new device for the purpose of treating serious eye diseases such as macular degeneration and retinitis pigmentosa. The technology emits low intensity pulse ultrasound into the eye for the purpose of regeneration...

2013-06-25 12:30:04

National research foundation awards $1.2 million to scientists in Italy, Netherlands and U.S. conducting groundbreaking research to find a cure for macular degeneration and other retinal diseases CONSHOHOCKEN, Pa., June 25, 2013 /PRNewswire-USNewswire/ -- The Macula Vision Research Foundation (MVRF), a national nonprofit focused on funding research to find a cure for macular degeneration and other retinal diseases including childhood blindness, announces their 2013-2014 grant...

Judge Rules Sarah Murnaghan Can Be On Adult Lung Transplant List
2013-06-06 12:28:12

Lee Rannals for redOrbit.com — Your Universe Online A federal judge has ruled that 10-year-old Sarah Murnaghan can be put on the list for a lung transplant. The young Pennsylvania patient has cystic fibrosis and was given just a few weeks to live if she did not receive a lung transplant. Doctors put her on a transplant list for adults because so few children's lungs become available. The adult list requires children to be at least 12-years-old. Secretary of Health and Human...

2013-05-30 23:00:55

Alex Brown and Erin Gillen join Kim Power Stilson on the TalkWorthy Radio Show to talk about the Utah Vision Walk. Blinding retinal degenerative diseases like retinitis pigmentosa, macular degeneration and Usher syndrome affect more than 10 million Americans, but the Foundation Fighting Blindness is funding cutting-edge studies toward preventions, treatments and cures. Salt Lake City, UT (PRWEB) May 30, 2013 Alex Brown and Erin Gillen, spokespersons for the 5th Annual Utah 5K VisionWalk on...

2013-05-01 12:28:03

- Forty students will receive $2,500 scholarships for the 2013-2014 school year NORTH CHICAGO, Ill., May 1, 2013 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the AbbVie CF Scholarship for the 2013-2014 academic school year. Previously known as the CFCareForward Scholarship, the AbbVie CF Scholarship was established 21 years ago to honor young adults with CF as they pursue goals of higher...

2013-04-13 23:03:04

Juanita McNeil releases inspirational guide to a pain-free life Richland, WA (PRWEB) April 13, 2013 From suffering abuse as a child to currently battling blindness, Juanita McNeil has overcome many challenges in her life. Though these hardships might keep many people down, they make McNeil strive to find the positives in life. At the age of 46, McNeil is currently attending school for her blindness caused by retinitis pigmentosa. Upon graduation from the Department for the Blind, she has...

2013-04-10 16:19:52

In a first-of-its-kind study, researchers from the United States and Europe discovered genetic mutations associated with long QT syndrome (LQTS), a genetic abnormality in the heart's electrical system, in a small number of intrauterine fetal deaths, according to a study in the April 10 issue of the Journal of the American Medical Association. Researchers conducted a molecular genetic evaluation (referred to as a postmortem cardiac channel molecular autopsy) in 91 cases of unexplained fetal...

2013-03-26 12:29:46

Calling on provincial governments to ensure CF patients receive equitable access to KALYDECO(TM) TORONTO, March 26, 2013 /CNW/ - As part of the Common Drug Review process, the Canadian Drug Expert Committee (CDEC) has recommended that the drug KALYDECO(TM) (ivacaftor) be listed on the formulary listing of publicly funded drug plans for the treatment of cystic fibrosis in patients age six years and older who have the G551D mutation in the Cystic Fibrosis Transmembrane conductance...

2013-03-13 08:30:43

BOULDER, Colo., March 13, 2013 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma") a leader in the development of therapeutics that target S-nitrosoglutathione reductase (GSNOR), announced today that it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis (CF). The study is a multicenter, double-blind, randomized, placebo-controlled evaluation of ascending doses of N6022 in patients who have two copies of the F508del-CFTR mutation,...

2013-02-21 08:31:32

ST. PETERSBURG, Fla., Feb. 21, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that it has acquired exclusive rights to a provisional patent application against Retinitis Pigmentosa. This exclusive intellectual property right, a result of Premier's long-standing licensing agreements, proposes a novel method for treating the degenerative eye disease via the targeted removal of specified target antigens. This is the latest of many proposed applications of Premier...


Latest Channelopathy Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »